Clinical trials: End-stage Liver Disease (ESLD)
End Stage Liver Disease
End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)
The purpose of this research study is to see how effective bioelectric impedance analysis (BIA) is in determining body composition (the amount of fat versus muscle in the body) and nutritional status in patients with End Stage…
- Trial name
- NCT00374582
- Testing
- Bodystat Quadscan 4000, bodystat quadscan 400
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
End-stage Liver Diseases
Effect of Different Dosage of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
There is a rise in the prevalence of end-stage liver disease during the last decade. End-stage liver disease has become one of the leading causes of death in Western countries.
- Trial name
- NCT06167473
- Testing
- umbilical cord-mesenchymal stem cells
- Where
- China
- Volunteers
- 22 people
- Sponsor
- General Hospital of Shenyang Military Region
End-Stage Liver Diseases
Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues.
- Trial name
- NCT06984497
- Testing
- Infusion of umbilical cord-mesenchymal stem cells through peripheral veins, Infusion of umbilical cord-mesenchymal stem cells through hepatic artery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- General Hospital of Shenyang Military Region
Transplant-Related Disorder
Albumin, COP and Endothelial Damage in Patients With ESLD Undergoing OLT
To study the correlation between colloid osmotic pressure, albumin and the loss of vascular integrity in terms of endothelial dysfunction in patients with ESLD undergoing OLT and its impact on the perioperative course, as well as…
- Trial name
- NCT03448679
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
End-stage Liver Disease (ESLD), Acute Liver Failure
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given…
- Conditions
- End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
- Trial name
- REFRAME-MP (NCT07585890)
- Testing
- Endischemic hypothermic oxygenated machine perfusion (any device), Endischemic (back-to-base) normothermic machine perfusion (any device), Continuous (device-to-donor) normothermic machine perfusion (any device)
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 10,000 people
- Sponsor
- University Medical Center Groningen
Liver Transplantation, Tranexamic Acid
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
We propose a multi-center randomized trial to test the primary hypothesis that tranexamic acid is superior to placebo on blood loss in adult orthotopic liver transplantation within the initial 24 hours and that tranexamic acid is…
- Conditions
- Liver Transplantation, Tranexamic Acid, End-stage Liver Disease (ESLD)
- Trial name
- ESTA (NCT07157631)
- Testing
- tranexamic acid, 0.9 % saline
- Where
- China
- Volunteers
- 1,546 people
- Sponsor
- RenJi Hospital
Liver Transplantation, End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL) - Pilot
Hypothesis: A Canadian multicentre clinical trial is feasible. Study Design: Multicenter internal pilot parallel arm randomized controlled trial.
- Trial name
- REFIL-1 (NCT05647733)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Optimized cardiac output liberal fluid management strategy, Phlebotomy
- Where
- 4 sites in Canada
- Volunteers
- 138 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
End-stage Liver Disease (ESLD), Cirrhosis, Liver
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and…
- Conditions
- End-stage Liver Disease (ESLD), Cirrhosis, Liver, Cirrhosis, Decompensated, Liver Diseases
- Trial name
- EMERALD (NCT06823713)
- Testing
- RTX001
- Where
- 15 sites in Spain, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Resolution Therapeutics Limited
Liver Cirrhosis
Study in Patients With Decompensated Liver Cirrhosis
OPAL is a multicenter observational study, following the natural disease trajectory of participants who have permanent damage to their liver caused by scarring, sometimes also referred to as liver cirrhosis.
- Trial name
- OPAL (NCT06380335)
- Where
- 12 sites in Spain, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Resolution Therapeutics Limited
End Stage Liver Disease, Hepatitis C
DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
This is a single center study for the donation of Hepatitis C Virus (HCV)-positive livers to HCV negative recipient patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.
- Trial name
- NCT03208127
- Testing
- Treatment with Direct Acting Antiviral tablet
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
End Stage Liver Disease, Hepatitis C
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.
- Trial name
- NCT00163657
- Testing
- Daclizumub, Tacrolimus, Cyclosporine
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Baylor Research Institute
End-stage Liver Disease (ESLD), Liver Transplant
A Physical Activity Program in End-state Liver Disease
The primary aim of this study is to improve both physical fitness and sarcopenia of patients with ESLD who are potentially eligible for liver transplantation through a 12-week physical training program.
- Conditions
- End-stage Liver Disease (ESLD), Liver Transplant, Sarcopenia, Poor Physical Fitness
- Trial name
- NCT02776553
- Testing
- Nutritional consultation, Physical training program, Behavioral modification therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
End Stage Liver Disease, Decompensated Cirrhosis of Liver
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e.
- Trial name
- PAL-LIVER (NCT03540771)
- Testing
- Palliative Care
- Where
- 19 sites in United States
- Volunteers
- 1,494 people
- Sponsor
- Albert Einstein Healthcare Network
Liver Transplant; Complications
Identifying Perceived Barriers and Facilitators Toward a Liver Transplantation Prehabilitation
The purpose of this study is to formally identify patient and caregiver perceived needs, barriers, and facilitators to inform the development of a home-based multimodal prehabilitation program for potential LT candidates.
- Trial name
- NCT04854564
- Testing
- Prehabilitation intervention, Caregiver intervention
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- University of Alabama at Birmingham
Liver Transplantation
Assessment of a Quantra-guided Transfusion Algorithm in Liver Transplantation
Liver transplantation carries a substantial risk of bleeding, making precise haemostasis control essential, although assessing coagulation remains challenging.
- Trial name
- QUALIVERT (NCT06749405)
- Testing
- Transfusion algorithm based on Quantra®, Conventional transfusion algorithm
- Where
- France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Toulouse
End Stage Liver Disease
Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies
Regulatory CD4+CD25+ T cells (Treg) derived from the thymus and/or periphery can control immune responsiveness to auto- and allo-antigens.
- Trial name
- NCT02447926
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
End-Stage Liver DIsease
Effect of Different Frequencies of Umbilical Cord-mesenchymal Stem Cells Through Peripheral Vein in Patients With ESLD
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues.
- Trial name
- NCT06242405
- Testing
- umbilical cord-mesenchymal stem cells
- Where
- China
- Volunteers
- 92 people
- Sponsor
- General Hospital of Shenyang Military Region
Liver Transplantation (LT), End-stage Liver Disease (ESLD)
Restrictive Fluid Management In Liver Transplantation (REFIL)
The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications…
- Trial name
- REFIL-2 (NCT07695363)
- Testing
- Low splanchnic blood volume restrictive fluid management strategy, Phlebotomy, Optimized cardiac output liberal fluid management strategy
- Where
- 4 sites in Canada
- Volunteers
- 866 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
End-stage Liver Disease (ESLD), Liver Transplantation
View of Cerebral Perfusion in Liver Transplantation
Investigator's aim in this study is to compare the more accessible and low-cost Carotid Doppler USG measurements, which are relatively more difficult to access, costly, and have technical disadvantages, and to demonstrate their…
- Conditions
- End-stage Liver Disease (ESLD), Liver Transplantation, Cerebral Perfusion, Intraoperative Monitoring
- Trial name
- NIRS/Doppler (NCT07442214)
- Testing
- Carotid Doppler Ultrasonography and Near-Infrared Spectroscopy (NIRS)
- Where
- Turkey (Türkiye)
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Inonu University